Lymphoma News and Research

RSS
Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.
New approaches to treating leukemia, lymphoma and myeloma

New approaches to treating leukemia, lymphoma and myeloma

Yale study identifies how myeloma cells escape treatment

Yale study identifies how myeloma cells escape treatment

Ibrutinib more effective than traditional chemotherapy in older untreated patients with CLL

Ibrutinib more effective than traditional chemotherapy in older untreated patients with CLL

Genetic variations associated with increased risk for osteonecrosis in young ALL patients

Genetic variations associated with increased risk for osteonecrosis in young ALL patients

Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

Potential for chemotherapy-free standard of care in advanced mantle cell lymphoma

Potential for chemotherapy-free standard of care in advanced mantle cell lymphoma

Discovery may lead to potential new therapeutic approach to eradicate blood cancers

Discovery may lead to potential new therapeutic approach to eradicate blood cancers

Prehospital combination therapy disappoints in status epilepticus

Prehospital combination therapy disappoints in status epilepticus

Epilepsy common but variable in mitochondrial disease patients

Epilepsy common but variable in mitochondrial disease patients

Comorbidities relevant to CML TKI choice common

Comorbidities relevant to CML TKI choice common

New combination approach to eradicate established tumors

New combination approach to eradicate established tumors

Leukemia & Lymphoma Society applauds FDA's recent approval of two new multiple myeloma drugs

Leukemia & Lymphoma Society applauds FDA's recent approval of two new multiple myeloma drugs

Crucial tumor-suppressing gene protects immune attack against lung cancer

Crucial tumor-suppressing gene protects immune attack against lung cancer

New drug screening method may predict treatment options for patients with multiple myeloma

New drug screening method may predict treatment options for patients with multiple myeloma

Many European hospitals fail to routinely test people at risk of HIV infection

Many European hospitals fail to routinely test people at risk of HIV infection

Health experts urge lawmakers, regulators to close loopholes in Orphan Drug Act

Health experts urge lawmakers, regulators to close loopholes in Orphan Drug Act

CRI scientists identify emergency blood-formation system inside the body

CRI scientists identify emergency blood-formation system inside the body

Patients with kidney failure at increased risk of developing different types of cancer

Patients with kidney failure at increased risk of developing different types of cancer

Drug combination produces long-term responses in patients with mantle cell lymphoma

Drug combination produces long-term responses in patients with mantle cell lymphoma

Phase I clinical trial shows investigational anticancer therapeutic is safe, tolerable in lymphoma patients

Phase I clinical trial shows investigational anticancer therapeutic is safe, tolerable in lymphoma patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.